LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 61

Search options

  1. Article: [No title information]

    Lauper, Kim

    Revue medicale suisse

    2024  Volume 20, Issue 858, Page(s) 132–134

    Title translation Polyarthrite rhumatoïde.
    MeSH term(s) Humans ; Arthritis, Rheumatoid
    Language French
    Publishing date 2024-01-25
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    DOI 10.53738/REVMED.2024.20.858.132
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5998: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Poussées de la polyarthrite rhumatoïde.

    Chaix, Edouard / Lauper, Kim

    Revue medicale suisse

    2023  Volume 19, Issue 818, Page(s) 517–520

    Abstract: Rheumatoid arthritis (RA) is a common chronic autoimmune inflammatory disease, primarily affecting the joints. Its activity is subject to exacerbations called flares. These RA flares are linked to cardiovascular, functional and radiological complications. ...

    Title translation Rheumatoid arthritis flares.
    Abstract Rheumatoid arthritis (RA) is a common chronic autoimmune inflammatory disease, primarily affecting the joints. Its activity is subject to exacerbations called flares. These RA flares are linked to cardiovascular, functional and radiological complications. The mechanisms behind these flares are still poorly understood. There is currently no reliable biomarker for the diagnosis of the flares. Diagnostic scores have been developed for research purposes but their application in clinical practice is not yet clear. The therapeutic approach includes acute treatment of the flare with corticosteroids and evaluation of the need for intensification of background therapy.
    MeSH term(s) Humans ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/diagnostic imaging ; Radiography
    Language French
    Publishing date 2023-03-15
    Publishing country Switzerland
    Document type English Abstract ; Journal Article
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    DOI 10.53738/REVMED.2023.19.818.517
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5998: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Rhumatologie en crise : repenser la formation et les soins face à un défi croissant.

    Lauper, Kim / Schürch, Marc-André / Gabay, Cem

    Revue medicale suisse

    2024  Volume 20, Issue 865, Page(s) 546–549

    Abstract: Musculoskeletal diseases, on the rise, pose a major challenge in French-speaking Switzerland where the shortage of rheumatologists is worsening, due to the aging of practitioners, a scarcity of emerging professionals, and a trend towards part-time work ... ...

    Title translation Rheumatology in crisis : rethinking training and care amidst a growing challenge.
    Abstract Musculoskeletal diseases, on the rise, pose a major challenge in French-speaking Switzerland where the shortage of rheumatologists is worsening, due to the aging of practitioners, a scarcity of emerging professionals, and a trend towards part-time work among young doctors. To address this, increasing rheumatology training positions and enhancing general practitioners' training in these pathologies are essential. The adoption of alternative care models, such as monitoring by specialized nurses and greater involvement of physiotherapists, should be considered. This evolution is crucial for patients, whose quality of life and health depend on the accessibility and effectiveness of adequate care. Therefore, concerted action is indispensable to ensure a sustainable and effective future for rheumatology in French-speaking Switzerland.
    MeSH term(s) Humans ; Rheumatology ; Quality of Life ; Rheumatologists ; Musculoskeletal Diseases/epidemiology ; Musculoskeletal Diseases/therapy ; Forecasting
    Language French
    Publishing date 2024-03-14
    Publishing country Switzerland
    Document type English Abstract ; Journal Article
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    DOI 10.53738/REVMED.2024.20.865.546
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5998: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: How effective are JAK-inhibitors? Perspectives from clinical trials and real-world studies.

    Lauper, Kim / Hyrich, Kimme L

    Expert review of clinical immunology

    2021  Volume 18, Issue 3, Page(s) 207–220

    Abstract: Introduction: JAK-inhibitors have emerged as a new treatment option for rheumatoid arthritis, with five molecules currently available in different parts of the world: tofacitinib, baricitinib, upadacitinib, peficitinib, and filgotinib. These molecules ... ...

    Abstract Introduction: JAK-inhibitors have emerged as a new treatment option for rheumatoid arthritis, with five molecules currently available in different parts of the world: tofacitinib, baricitinib, upadacitinib, peficitinib, and filgotinib. These molecules have been the subject of numerous trials looking at their efficacy (how well they perform in controlled conditions) but also some observational studies from the general population to assess their effectiveness (how well treatment perform under real conditions). With each their own weaknesses and strengths, they give different but complementary information.
    Areas covered: We will review what we can learn from trials and real-world studies on how effective JAK-inhibitors are in the treatment of rheumatoid arthritis.
    Expert opinion: Trials of JAK-inhibitors have shown that JAK-inhibitors are efficacious for the treatment of rheumatoid arthritis. However, their main outcomes are not clinically meaningful as their aim is mainly the regulatory authorization of the product. Real-world studies are important as they evaluate the real-life effectiveness of the compounds, however, they are scarce at the moment, mainly evaluating tofacitinib and of variable quality. Future high-quality studies are needed to assess the real-world effectiveness of JAK-inhibitors in a more complete manner.
    MeSH term(s) Antirheumatic Agents/pharmacology ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Clinical Trials as Topic ; Humans ; Janus Kinase Inhibitors/therapeutic use ; Observational Studies as Topic
    Chemical Substances Antirheumatic Agents ; Janus Kinase Inhibitors
    Language English
    Publishing date 2021-10-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 2274260-8
    ISSN 1744-8409 ; 1744-666X
    ISSN (online) 1744-8409
    ISSN 1744-666X
    DOI 10.1080/1744666X.2021.1982383
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6661: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Rhumatologie : ce qui a changé en 2022.

    Iudici, Michele / Lazarou, Ilias / Nissen, Michael J / Lauper, Kim

    Revue medicale suisse

    2023  Volume 19, Issue 812, Page(s) 239–242

    Abstract: In rheumatology, this year has seen an expansion of knowledge about the treatment of rheumatoid arthritis, with the availability of results from randomized trials evaluating a new molecule targeting IL-6, and regarding the safety profile of tofacitinib ... ...

    Title translation Rheumatology : what's new in 2022.
    Abstract In rheumatology, this year has seen an expansion of knowledge about the treatment of rheumatoid arthritis, with the availability of results from randomized trials evaluating a new molecule targeting IL-6, and regarding the safety profile of tofacitinib compared to TNF-alpha inhibitors. Interesting data on the outcome of pregnancy in patients with spondylarthritis have also been published. New molecules and different treatment strategies have shown promising results in psoriatic arthritis and systemic lupus erythematosus. The utility of botulinum toxin A injections for Raynaud's phenomenon and the efficacy of transplantation of autologous adipose-derived regenerative cells for the treatment of hand dysfunctions have been questioned by 2 randomized controlled trials of patients with systemic sclerosis.
    MeSH term(s) Humans ; Rheumatology ; Botulinum Toxins, Type A ; Arthritis, Rheumatoid/drug therapy ; Lupus Erythematosus, Systemic ; Scleroderma, Systemic/therapy
    Chemical Substances Botulinum Toxins, Type A (EC 3.4.24.69)
    Language French
    Publishing date 2023-02-01
    Publishing country Switzerland
    Document type English Abstract ; Journal Article
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    DOI 10.53738/REVMED.2023.19.812.239
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5998: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Brief report: can COVID-19 infection trigger rheumatoid arthritis-associated autoimmunity in individuals at risk for the disease? A nested cohort study.

    Lamacchia, Celine / Gilbert, Benoit / Studer, Olivia / Lauper, Kim / Finckh, Axel

    Frontiers in medicine

    2023  Volume 10, Page(s) 1201425

    Abstract: Objectives: To investigate the association between severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2) infection and subsequent development of autoimmunity or pre-clinical manifestations associated with rheumatoid arthritis (RA) in ... ...

    Abstract Objectives: To investigate the association between severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2) infection and subsequent development of autoimmunity or pre-clinical manifestations associated with rheumatoid arthritis (RA) in at risk population.
    Methods: This is a nested study within a prospective cohort of first-degree relatives of RA patients (RA-FDR). Participants are tested for RA-associated autoantibodies (anti-citrullinated peptide antibodies (ACPA)/rheumatoid factor (RF)) and clinical signs and symptoms suggestive of early disease. SARS-CoV-2 infections were self-reported between March 2020 and January 2023. All individuals with a pre-pandemic (sample 1) and a post-pandemic sample (sample 2) were included in the analysis. The exposure of interest was self-reported SARS-CoV-2 infection. The primary outcome was a clinically significant change in RA-associated autoantibody serum titers. Secondary outcomes included: becoming seropositive, becoming symptomatic, developing classifiable RA.
    Results: Among 168 RA-FDRs, 109 reported a SARS-CoV-2 infection between sample 1 and sample 2. During this period, 2 RA-FDRs (1.2%) became anti-CCP2 seropositive, none became anti-CCP3 IgG positive, 6 (3.6%) became RF IgM seropositive, 1 became (0.6%) RF IgA seropositive, 19 (11.3%) became symptomatic and none developed classifiable RA. SARS-CoV-2 infection was not significantly associated with increases in RA autoantibody titers or with secondary outcomes.
    Conclusion: We could not detect an association between SARS-CoV-2 infection and subsequent development of RA-associated autoimmunity, nor signs or symptoms of RA in an at risk population. These findings do not support the hypothesis that SARS-CoV-2 infections triggers the immune onset of RA.
    Language English
    Publishing date 2023-07-07
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2023.1201425
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Prévention vaccinale chez les patients avec des maladies rhumatismales.

    Finckh, Axel / Eperon, Gilles / Lauper, Kim

    Revue medicale suisse

    2022  Volume 18, Issue 773, Page(s) 482–486

    Abstract: Patients with inflammatory rheumatologic diseases are at increased risk for infectious complications, including SARS-CoV-2, which represent one of the leading causes of death in this population. This risk is due to both the numerous comorbidities of this ...

    Title translation Vaccine prevention in patients with rheumatic diseases.
    Abstract Patients with inflammatory rheumatologic diseases are at increased risk for infectious complications, including SARS-CoV-2, which represent one of the leading causes of death in this population. This risk is due to both the numerous comorbidities of this patient's group and the immunosuppressive therapies they receive. Vaccination reduces the incidence, complications, and mortality from infections. For patients receiving immunosuppressors, exacerbation of underlying diseases is rarely observed after immunization and only live-attenuated vaccines are contraindicated. A vaccination history and updated vaccination plan should be part of the clinical follow-up of patients with inflammatory rheumatism.
    MeSH term(s) COVID-19/prevention & control ; Humans ; Rheumatic Diseases/drug therapy ; SARS-CoV-2 ; Vaccination/adverse effects ; Vaccines
    Chemical Substances Vaccines
    Language French
    Publishing date 2022-03-20
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    DOI 10.53738/REVMED.2022.18.773.482
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5998: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Predictive factors of treatment persistence in rheumatoid arthritis.

    Lauper, Kim / Finckh, Axel

    Joint bone spine

    2020  Volume 87, Issue 6, Page(s) 531–534

    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/drug therapy ; Humans
    Chemical Substances Antirheumatic Agents
    Language English
    Publishing date 2020-03-25
    Publishing country France
    Document type Editorial
    ZDB-ID 2020487-5
    ISSN 1778-7254 ; 1297-319X
    ISSN (online) 1778-7254
    ISSN 1297-319X
    DOI 10.1016/j.jbspin.2020.03.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4590: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Petites molécules dans la polyarthrite rhumatoïde.

    Verdon, Aurore / Lauper, Kim

    Revue medicale suisse

    2020  Volume 16, Issue 685, Page(s) 477–480

    Abstract: If treatment target is not reached with a conventional disease-modifying antirheumatic drug (csDMARD) such as methotrexate in rheumatoid arthritis, it is recommended to use a biologic (bDMARD) or a Janus kinase (JAK) inhibitor, small synthetic molecules ... ...

    Title translation Small molecules treatment in rheumatoid arthritis.
    Abstract If treatment target is not reached with a conventional disease-modifying antirheumatic drug (csDMARD) such as methotrexate in rheumatoid arthritis, it is recommended to use a biologic (bDMARD) or a Janus kinase (JAK) inhibitor, small synthetic molecules recently developed. Oral administration and short half-life can favour the choice of JAK inhibitors, as well as the opportunity to use it in monotherapy, even though co-treatment with csDMARD is recommended. As yet long-term studies are lacking, little is known about adverse effects although risk of herpes virus infections is clearly higher with JAK inhibitors than bDMARD treatments.
    MeSH term(s) Antirheumatic Agents/administration & dosage ; Antirheumatic Agents/adverse effects ; Antirheumatic Agents/chemistry ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Drug Therapy, Combination ; Humans ; Janus Kinase Inhibitors/administration & dosage ; Janus Kinase Inhibitors/adverse effects ; Janus Kinase Inhibitors/chemistry ; Janus Kinase Inhibitors/therapeutic use ; Methotrexate/therapeutic use ; Treatment Outcome
    Chemical Substances Antirheumatic Agents ; Janus Kinase Inhibitors ; Methotrexate (YL5FZ2Y5U1)
    Language French
    Publishing date 2020-03-17
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5998: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Rhumatologie: ce qui a changé en 2023.

    Lauper, Kim / Finckh, Axel / Genevay, Stéphane / Girard-Guyonvarc'h, Charlotte / Guemara, Romain / Nissen, Michael J / Iudici, Michele

    Revue medicale suisse

    2024  Volume 20, Issue 856-7, Page(s) 102–105

    Abstract: In rheumatology, this year has been characterized by a broader knowledge of the pathogenesis of rheumatoid arthritis and mechanisms involved in the onset and persistence of low back pain. Studies relevant to the management of of gout, axial ... ...

    Title translation Rheumatology: what's new in 2023.
    Abstract In rheumatology, this year has been characterized by a broader knowledge of the pathogenesis of rheumatoid arthritis and mechanisms involved in the onset and persistence of low back pain. Studies relevant to the management of of gout, axial spondyloarthritis, autoinflammatory diseases and systemic vasculitides were published. New data on the safety of JAK inhibitors have been published. The ASAS-EULAR recommendations for the treatment of axial spondyloarthritis were updated, and the 2023 EULAR/PReS guidelines for the diagnosis and treatment of systemic juvenile idiopathic arthritis and adult-onset Still's disease are now available. New molecules and different glucocorticoid sparing strategies were introduced for giant cell arteritis.
    MeSH term(s) Adult ; Humans ; Rheumatology ; Arthritis, Juvenile ; Arthritis, Rheumatoid ; Giant Cell Arteritis/diagnosis ; Giant Cell Arteritis/therapy ; Axial Spondyloarthritis
    Language French
    Publishing date 2024-01-17
    Publishing country Switzerland
    Document type English Abstract ; Journal Article
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    DOI 10.53738/REVMED.2024.20.856-7.102
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5998: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top